Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ligand Earns Merck Milestone for NOXAFIL Infusion Approval | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Ligand Earns Merck Milestone for NOXAFIL Infusion Approval

Will sell Captisol-enabled formulation to Merck

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ligand Pharmaceuticals has received a $550,000 milestone payment following Merck’s EMA approval of NOXAFIL (posaconazole) 300 mg Concentrate Solution for Infusion. Ligand will sell Captisol to Merck for the product marketed in Europe under an existing commercial supply agreement. Captisol is a patented, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs.

NOXAFIL is a triazole antifungal agent with activity against both yeast and molds responsible for serious invasive fungal infections. Merck also markets oral suspension and tablet formulations of NOXAFIL.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics